In this study, the patients will randomly receive either Promacta/Vidaza combination every 28 days for at least 6 cycles, or placebo plus Vidaza. The primary endpoint of the study is to compare the ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
First supportive care treatment approved for patients with thrombocytopenia with chronic hepatitis C to allow the initiation and maintenance of interferon-based therapy LONDON, Nov. 19, 2012 ...
GlaxoSmithKline (NYSE:GSK) now wants approval to use its low platelet drug Promacta to treat hepatitis C patients. The British pharmaceutical giant, which has its U.S. headquarters in Research ...
Promacta (eltrombopag) is a brand-name drug prescribed for certain blood conditions. Promacta has interactions with some supplements and drugs. Examples include some antacids and certain statins. An ...
Recently, the FDA granted a breakthrough therapy designation to eltrombopag (Promacta, Novartis) for combination use with standard immunosuppressive therapy as a first-line treatment for patients with ...
PHILADELPHIA, Dec. 6 GlaxoSmithKline (NYSE: GSK)announced positive safety and efficacy results from RAISE (RAndomized placebo-controlled ITP Study with Eltrombopag), a Phase III study of ...
CHICAGO, May 30 (Reuters) - An expert advisory panel to the U.S. Food and Drug Administration said on Friday that current clinical data supports short-term use of GlaxoSmithKline Plc's experimental ...
(HealthDay)—U.S. Food and Drug Administration approval of the drug Promacta (eltrombopag) has been expanded to include children one year and older with a rare blood disorder called chronic immune ...
The company is recalling the lots because of possible peanut flour contamination. Novartis announced on May 11, 2019 that it was recalling three lots of Promacta (eltrombopag) 12.5 mg for oral ...
SAN DIEGO--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that PROMACTA® (eltrombopag), a drug discovered in collaboration with GlaxoSmithKline (NYSE:GSK), was ...
SAN DIEGO & NEW YORK--(BUSINESS WIRE)--Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) and Royalty Pharma announce the sale of Ligand’s Promacta ®-related intellectual property rights licensed to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results